An overview of the pharmaceutical market for Tenofovir-Emtracitabine-Efavirenz (TEE) and Tenofovir-Lamivudine-Dolutegravir (TLD) within the South African private sector

The scale up of access to HIV care and treatment is critical to the success of achieving the UNAIDS 95-95-95 goals in South Africa (SA)(1). There were an estimated 5.4 million people on Antiretroviral therapy (ART) in the SA public sector in 2021, including 137,655 children (<15 years) and 5,328,800 adults(2). Despite the large HIV burden, it is estimated that only 62% of the 7.5 million people who are living with HIV (PLHIV) in the country are on ART.